Review Article | Open Access
Aoife J. McCarthy, Runjan Chetty, "Benign Smooth Muscle Tumors (Leiomyomas) of Deep Somatic Soft Tissue", Sarcoma, vol. 2018, Article ID 2071394, 6 pages, 2018. https://doi.org/10.1155/2018/2071394
Benign Smooth Muscle Tumors (Leiomyomas) of Deep Somatic Soft Tissue
Leiomyomas of deep soft tissue are extremely rare and should only be diagnosed following adherence to stringent histological criteria, namely, the absence of nuclear atypia and of coagulative tumor necrosis. Whether extremely low counts of, or even any, mitotic activity are acceptable when making a diagnosis of leiomyoma in deep soft tissue sites is controversial. The morphology and immunophenotype of smooth muscle tumors in deep soft tissue are similar to their counterparts irrespective of topography. It is interesting to note that leiomyomas of deep soft tissue (extremity and retroperitoneum) are often hyalinized/sclerosed and calcified. However, the prediction of their behavior and correct codification is dependent on thorough, meticulous search for mitoses and necrosis. Leiomyomas of deep soft tissue in the extremity should be devoid of mitoses and “significant” cytological atypia. An occasional larger, slightly pleomorphic cell in the midst of bland spindle cells, can be regarded as insignificant atypia. If any mitotic activity and several atypical cells are encountered in smooth muscle tumors of deep soft tissue of the extremity, it would be prudent to invoke the appellation of smooth muscle tumor of uncertain malignant potential and advocate wide local excision and follow-up.
In the past, the existence of leiomyomas of deep soft tissue was considered controversial. The prevailing view was that most, and perhaps all, smooth muscle tumors of deep soft tissue were malignant, although this was based on studies of smooth muscle tumors demonstrating both mitotic activity and cytological atypia. To date, there have been very few studies of well-differentiated smooth muscle tumors of deep soft tissue that display an absence of mitotic activity and cytological atypia. It is now thought that, although they are exceptionally rare, deep soft tissue leiomyomas do in fact exist [1–8] and can occur in somatic soft tissue or in the retroperitoneum and abdominal cavity.
The focus of this succinct review is on leiomyomas of deep somatic soft tissue.
2. Clinical Features
Leiomyomas of deep somatic soft tissue occur primarily in middle-aged adults, with a mean age of 37 years, and with equal distribution among the genders . Deep somatic soft tissue of the lower extremity, usually the thigh, is the most common site, followed by the upper extremity and the trunk . Many of these lesions are calcified, likely resulting from regressive changes, and can be detected radiographically [4, 5, 11–13]. The radiological appearances are usually nonspecific, and differential diagnoses include calcifying schwannoma, chondroma, myositis ossificans, tumoral calcinosis, chondrosarcoma, and synovial sarcoma . Thus, wide local excision is required for definitive classification.
3. Gross Appearance
Grossly, the majority of deep somatic soft tissue leiomyomas are circumscribed masses, with a tan-grey to white cut surface, and a mean size of 5.4 cm. Degenerative mucoid-cystic change is occasionally present .
4. Histological Features
Microscopically, deep soft tissue benign smooth muscle tumors are often well-circumscribed, unencapsulated, occasionally multinodular, paucicellular spindle cell lesions (Figure 1(a)). The lesional cells are bland, cigar-shaped spindle cells, with indistinct cell borders and abundant light to deeply eosinophilic cytoplasm arranged in oblique or perpendicular fascicles (Figure 1(b)). Stromal hyalinization occurs in the majority of cases and ranges from mild perivascular hyalinization to dense hyalinization (Figure 1(c)). Prominent stromal calcification is present in many of these lesions , and osseous metaplasia can also be encountered (Figure 1(d)). There is no evidence of mitotic activity, and nuclear pleomorphism and coagulative tumor necrosis are absent (Table 1).
M, male; F, female; HPF, high power fields; IHC, immunohistochemistry; ER, estrogen receptor protein; PR, progesterone receptor protein; SMTs, smooth muscle tumors; WLE, wide local excision; F/U, follow-up. The authors concluded that a smooth muscle tumor of somatic soft tissue with 1–5 mitoses/50 HPF should be regarded as “leiomyoma of uncertain malignant potential.”
While an important diagnostic tenet of leiomyomas of deep somatic soft tissue is that nuclear atypia is lacking in the majority, focal minimal atypia has been described in a few cases . Mitoses are very rarely identified and typically do not number more than 1 mitosis per 50 high power fields (HPF). Atypical mitotic figures are not present . It is essential to search assiduously for the presence of “coagulative tumor necrosis,” and this must be distinguished from “hyaline necrosis.” Hyaline necrosis is characterized by necrosis which is separated from viable tumor by a zone of connective tissue that varies from granulation tissue to hyalinized fibrous tissue, depending on the age of the necrosis . In contrast, coagulative tumor necrosis is defined by an abrupt transition from viable cells to necrotic cells without the interposed zone of granulation or fibrous tissue of infarct-type necrosis . The presence of coagulative tumor necrosis is not compatible with a diagnosis of benign smooth muscle tumor or leiomyoma in deep somatic soft tissue.
In 2001, Billings and colleagues analyzed the clinicopathological features of 13 highly differentiated smooth muscle tumors/leiomyomas of deep somatic soft tissue (as well as, but separately to, those in the retroperitoneum and abdominal cavity) to determine if it is indeed possible to define a biologically benign group of smooth muscle tumors at this site by using stringent criteria . Nuclear atypia was lacking in the majority of leiomyomas of deep somatic soft tissue in their series, although minimal atypia of a focal nature was present in occasional cases. 11 of 13 cases had a mitotic index of ≤1 mitosis/50 HPF, and all cases had a mitotic count ≤4 mitoses/50 HPF. The authors stress that, in assessing smooth muscle tumors of deep soft tissue, it is essential to distinguish coagulative tumor necrosis from hyaline necrosis, and none of their cases contained the former .
Billings et al. cautioned that their study encountered three leiomyomas of somatic soft tissue with low levels of mitotic activity (1–4 mitoses per 50 HPF), all of which occurred in young individuals (ages 6, 12, and 21 years, resp.) . Follow-up was available for two of these patients, ranging from 4 to 38 months only, and both patients had no adverse events. Although it is well established that mitotic activity of bona fide leiomyosarcomas of deep somatic soft tissue is usually higher than that in these 3 cases , given the absence of long-term follow-up for these patients, it is reasonable to be cautious in classifying these lesions as outright benign leiomyomas . Thus, the authors concluded that highly/well-differentiated smooth muscle tumors of deep somatic soft tissue with minimal/low mitotic activity should be designated as smooth muscle tumors of uncertain malignant potential, until proven otherwise .
5. Immunohistochemistry and Ancillary Tests
Leiomyomas of deep somatic soft tissue are positive for smooth muscle actin (SMA), desmin, and caldesmon (Figure 2) and expectedly are negative for a range of markers including cytokeratins, S100 protein, SOX-10, and CD34.
Genetics of deep soft tissue smooth muscle tumors are as yet poorly understood, and it remains to be seen if genes such as MED12 are indeed mutated in this particular group of benign smooth muscle tumors. Therefore, such diagnostic testing is not yet generally applicable in this histogenetic group.
6. Differential Diagnosis
Differential diagnoses of benign smooth muscle tumors (leiomyomas) of deep somatic soft tissue include both benign and malignant entities.
Angioleiomyoma is the most common peripheral soft tissue leiomyoma, typically occurring in the subcutis of extremities, particularly the lower leg, but also in the trunk wall and less commonly in the head and neck region. It usually forms a small 1-2 cm well-circumscribed, homogeneous rubbery nodule, and it is clinically notable for often being painful . Histologically, angioleiomyomas are composed of eosinophilic smooth muscle cells intimately associated with a vein wall, forming swirling congeries of spindle cells closely apposed to the vessel wall. The recognized variants are solid (very small lumens), venous (medium-size lumens), and cavernous (large lumens and thin smooth muscle elements in between) . Focal calcification can be present . Angioleiomyomas have an identical immunophenotype to leiomyomas of deep soft tissue, being positive for SMA and desmin and negative for S100 protein . Some examples of angioleiomyoma are positive for CD34 . Thus, the identification of the association with a vein wall is key in distinguishing angioleiomyoma from leiomyomas of deep soft tissue.
6.2. Epstein–Barr Virus- (EBV-) Associated Smooth Muscle Tumor
EBV-associated smooth muscle tumor is a rare subset of smooth muscle tumor that occurs in immunosuppressed individuals. It is most common in patients with human immunodeficiency virus (HIV), many of whom are young, including children. EBV-associated smooth muscle tumors also occur in solid organ transplant recipients (liver, kidney, and heart), who are usually middle-aged adults, and rarely in patients with a congenital immunodeficiency disorder . It can occur in peripheral soft tissue, as well as in the intracranial space, or visceral sites [16, 19]. Histologically, EBV-associated smooth muscle tumors consist of a fascicular arrangement of relatively well-differentiated smooth muscle cells with brightly eosinophilic cytoplasm and elongated, blunt-ended nuclei exhibiting variable atypia . Necrosis may be present, and variable mitotic activity can be seen . The two important defining and unique features are the presence of variable numbers of intratumoral T-lymphocytes and of so-called primitive round cell areas arising gradually or abruptly from the well-differentiated smooth muscle cells . They are no longer subdivided morphologically into EBV-associated leiomyomas and leiomyosarcomas, but all are categorized under the umbrella term of EBV-associated smooth muscle tumors. These tumors are SMA positive but are often desmin negative. A prerequisite for the distinction of EBV-associated smooth muscle tumors from leiomyomas of deep soft tissue is the demonstration of EBV-RNA by in situ hybridization, which highlights the tumor cell nuclei of EBV-associated smooth muscle tumors. It is essential to correctly identify this category of smooth muscle tumors, as, although they are usually indolent, they can be attended by a somewhat unpredictable behavior.
Smooth muscle tumors in soft tissue that contain both nuclear atypia and mitotic activity are generally designated leiomyosarcomas to denote their malignant (metastatic) potential . Histologically, leiomyosarcomas are composed of irregularly intersecting fascicles of spindled cells with variably eosinophilic cytoplasm and variable mitotic activity . Nuclei are typically blunt-ended, cigar-shaped, and these histological features are sufficient for the recognition of most leiomyosarcomas . A great majority of soft tissue leiomyosarcomas are of intermediate or high grade, and low-grade tumors are rare. Focal pleomorphism is common even in low-grade tumors with low mitotic activity. Immunohistochemically, leiomyosarcomas are almost invariably strongly positive for SMA, and desmin is usually positive (70–80%), along with positivity for heavy-caldesmon and smooth muscle myosin .
6.4. Other Spindle Cell Neoplasms
These include nerve sheath tumors, fibrohistiocytic spindle cell lesions, and sundry spindle cell lesions with characteristic immunophenotypic profiles.
The small number of cases with limited follow-up period reported in the literature precludes definitive conclusions regarding the significance of low mitotic rates in smooth muscle tumors of deep somatic soft tissue.
In the study by Billings and colleagues, clinical follow-up information was available for 11 of 13 of their patients, with a mean follow-up period of 58.7 months . Although 5 of 13 cases had positive resection margins, tumor recurrences or metastases were not documented .
However, recurrence has been reported in a smooth muscle tumor of somatic deep soft tissue with a mitotic activity of 1 mitosis per 50 HPF . Fletcher et al. reported a thoroughly sampled case displaying a bland, smooth muscle lesion from the left ischiorectal fossa of a 42-year-old woman . There was no evidence of cytological atypia or coagulative tumor necrosis, and there was 1 mitosis per 50 HPF. However, 16 months after resection, this lesion recurred and was now more cellular, with up to 4 mitoses per 10 HPF. This prompted the authors to conclude that any mitosis in smooth muscle tumors of subcutaneous or deep soft tissue should indicate potential malignancy, requiring wide local excision and careful follow-up . This sentiment was echoed by Billings and colleagues, who suggested, as outlined previously, that well-differentiated smooth muscle tumors of deep somatic soft tissue with minimal/low mitotic activity should be considered tumors of uncertain malignant potential .
These lesions are managed by wide local excision. Although 5 of 13 cases reported by Billings et al. had positive resection margins, tumor recurrences or metastases were not documented . The most appropriate follow-up for highly differentiated smooth muscle tumors of deep somatic soft tissue with minimal/low mitotic activity (tumors of uncertain malignant potential) has yet to be established.
9. Benign Smooth Muscle Tumors (Leiomyomas) of the Pelvic Retroperitoneum
As alluded to previously, leiomyomas of deep soft tissue segregate into two distinct clinicopathological groups, one group occurring in deep somatic soft tissue (the topic of this review) and the second occurring primarily in women in the pelvic retroperitoneum. For completeness, benign smooth muscle tumors (leiomyomas) of the pelvic retroperitoneum will be discussed briefly (Table 2).
M, male; F, female; HPF, high power fields; IHC, immunohistochemistry; ER, estrogen receptor protein; PR, progesterone receptor protein. The authors concluded that a smooth muscle tumor of retroperitoneum with >10 mitoses/50 HPF should be regarded as “smooth muscle tumors of uncertain malignant potential.”
Retroperitoneal leiomyomas occur preferentially in women during the perimenopausal period, usually in the pelvic retroperitoneum , and the lesions may be multiple [10, 22]. The histological appearance is per that described above for deep somatic soft tissue leiomyomas. However, unlike somatic soft tissue leiomyomas, 20% of retroperitoneal/abdominal leiomyomas display low levels of mitotic activity (1–5 mitoses per 50 HPF) . Despite this feature, less than 10% of lesions recur, and none have metastasized in follow-up periods averaging from 42 to 142 months [10, 20]. These tumors are commonly positive for estrogen receptor and progesterone receptor proteins .
Similar to uterine leiomyomas [23, 24], mutations in exon 2 of the MED12 gene have been reported in extrauterine leiomyomas, including at pelvic/retroperitoneal sites [25, 26]. Recently, Panagopoulos and colleagues presented the results of eight leiomyomas of deep soft tissue (all were located in the retroperitoneum or in the abdominal/pelvic cavity) that were genetically analyzed . Three tumors carried rearrangements of the long arm of chromosome 12 (the target gene of this 12q aberration was HMGA2), three others had 8q rearrangements (the target gene of the 8q aberration was PLAG1), one tumor had deletion of the long arm of chromosome 7, del(7) (q22), and one had aberrations of chromosome bands 3q21∼23 and 11q21∼22 . All eight leiomyomas of deep soft tissue expressed MED12 but none of them had mutation in exon 2 of that gene . Thus, it seems that smooth muscle tumors of deep somatic soft tissue are subject to some of the same mutational changes as those of their uterine counterparts and that genetic heterogeneity is a feature of these tumors. However, further interrogation is required.
The striking female predilection of this type of leiomyoma suggests that they arise from hormonally sensitive smooth muscle and are functionally similar to uterine leiomyomas . The location of these lesions and the fact that many women with these lesions had hysterectomies years previously suggest that these are not simply detached or parasitic uterine leiomyomas . It is thought that, like uterine leiomyomas, mitotic activity probably does not signify malignancy in the absence of other adverse histological parameters, such as cytological atypia and coagulative necrosis .
The diagnosis of leiomyoma in deep somatic soft tissue sites should be based on stringent histological criteria, specifically extremely low levels of, or even perhaps absence of, mitotic activity and the absence of nuclear atypia and coagulative tumor necrosis . Leiomyomas of deep somatic soft tissue diagnosed as such are expected to have an excellent outcome. It is, however, prudent to remember that these lesions are rare and are far outnumbered by their malignant counterpart; therefore, these lesions must be thoroughly sampled/all embedded and closely evaluated for the presence of cytological atypia, mitotic activity, and necrosis. The presence of low mitotic activity in otherwise differentiated smooth muscle tumors of deep somatic soft tissue without coagulative tumor necrosis should prompt a diagnosis of a smooth muscle tumor of uncertain malignant potential.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
- A. H. Goodman and R. C. Briggs, “Deep leiomyoma of an extremity,” Journal of Bone & Joint Surgery, vol. 47, no. 3, pp. 529–532, 1965.
- E. J. Drew, “Large leiomyoma of the upper extremity,” American Journal of Surgery, vol. 112, no. 6, pp. 938–940, 1966.
- J. H. Bulmer, “Smooth muscle tumors of the limbs,” Journal of Bone and Joint Surgery, British Volume, vol. 49, pp. 52–58, 1967.
- J. Ledesma-Medina, K. S. Oh, and B. R. Girdany, “Calcification in childhood leiomyoma,” Radiology, vol. 135, no. 2, pp. 339–341, 1980.
- K. Herrlin, H. Willén, and A. Rydholm, “Deep-seated soft tissue leiomyomas. Report of four patients,” Skeletal Radiology, vol. 19, no. 5, pp. 363–365, 1990.
- J. W. Smith, A. Danon, D. Padgett, and N. Johanson, “Leiomyomas of the lower extremity,” Orthopedics, vol. 14, no. 5, pp. 594–597, 1991.
- F. López-Barea, J. L. Rodríguez-Peralto, E. Burgos, and J. González-López, “Calcified leiomyoma of deep soft tissue. Report of a case in childhood,” Virchows Archiv, vol. 425, no. 2, pp. 217–220, 1994.
- G. M. Watson, A. Saifuddin, and A. Sandison, “Deep soft tissue leiomyoma of the thigh,” Skeletal Radiology, vol. 28, no. 7, pp. 411–414, 1999.
- S. E. Kilpatrick, T. Mentzel, and C. D. Fletcher, “Leiomyoma of deep soft tissue. Clinicopathologic analysis of a series,” American Journal of Surgical Pathology, vol. 18, no. 6, pp. 576–582, 1994.
- S. D. Billings, A. L. Folpe, and S. W. Weiss, “Do leiomyomas of deep soft tissue exist? An analysis of highly differentiated smooth muscle tumors of deep soft tissue supporting two distinct subtypes,” American Journal of Surgical Pathology, vol. 25, no. 9, pp. 1134–1142, 2001.
- L. S. Ross, M. R. Eckstein, R. Hirschhorn, A. H. Khapra, S. Shulman, and R. J. Hochstim, “Calcified leiomyoma: an unusual cause of large soft-tissue calcification of calf in childhood,” New York State Journal of Medicine, vol. 83, no. 5, pp. 747–749, 1983.
- P. R. Lubbers, R. Chandra, B. M. Markle, E. F. Downey Jr., and M. Malawer, “Case report 421: calcified leiomyoma of the soft tissues of the right buttock,” Skeletal Radiology, vol. 16, no. 3, pp. 252–256, 1987.
- E. H. De Mouy, K. Kaneko, and R. P. Rodriguez, “Calcified soft tissue leiomyoma of the shoulder mimicking a chondrogenic tumor,” Clinical Imaging, vol. 19, no. 1, pp. 4–7, 1995.
- S. W. Bell, R. L. Kempson, and M. R. Hendrickson, “Problematic uterine smooth muscle neoplasm: a clinicopathologic study of 213 cases,” American Journal of Surgical Pathology, vol. 18, no. 6, pp. 535–538, 1994.
- G. Farshid, M. Pradhan, J. Goldblum, and S. W. Weiss, “Leiomyosarcoma of somatic soft tissues: a tumor of vascular origin with multivariate analysis of outcome in 42 cases,” American Journal of Surgical Pathology, vol. 26, no. 1, pp. 14–24, 2002.
- M. Miettinen, “Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis,” Modern Pathology, vol. 27, no. 1, pp. S17–S29, 2014.
- A. Matsuyama, M. Hisaoka, and H. Hashimoto, “Angioleiomyoma: a clinicopathologic and immunohistochemical reappraisal with special reference to the correlation with myopericytoma,” Human Pathology, vol. 38, no. 4, pp. 645–651, 2007.
- J. Dekate and R. Chetty, “Epstein-Barr virus-associated smooth muscle tumor,” Archives of Pathology & Laboratory Medicine, vol. 140, no. 7, pp. 718–722, 2016.
- A. T. Deyrup, V. K. Lee, C. E. Hill et al., “Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients,” American Journal of Surgical Pathology, vol. 30, no. 1, pp. 75–82, 2006.
- C. D. Fletcher, S. E. Kilpatrick, and T. Mentzel, “The difficulty in predicting behavior of smooth-muscle tumors in deep soft tissue,” American Journal of Surgical Pathology, vol. 19, no. 1, pp. 116-117, 1995.
- S. W. Weiss, “Smooth muscle tumors of soft tissue,” Advances in Anatomic Pathology, vol. 9, no. 6, pp. 351–359, 2002.
- E. Paal and M. Miettinen, “Retroperitoneal leiomyomas: a clinicopathologic and immunohistochemical study of 56 cases with a comparison to retroperitoneal leiomyosarcomas,” American Journal of Surgical Pathology, vol. 25, no. 11, pp. 1355–1363, 2001.
- D. N. Markowski, S. Bartnitzke, T. Löning et al., “MED12 mutations in uterine fibroids–their relationship to cytogenetic subgroups,” International Journal of Cancer, vol. 131, no. 7, pp. 1528–1536, 2012.
- M. Mehine, N. Mäkinen, H. R. Heinonen et al., “Genomics of uterine leiomyomas: insights from high-throughput sequencing,” Fertility and Sterility, vol. 102, no. 3, pp. 621–629, 2014.
- K. E. Schwetye, J. D. Pfeifer, and E. J. Duncavage, “MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors,” Human Pathology, vol. 45, no. 1, pp. 65–70, 2014.
- G. Ravegnini, A. Mariño-Enriquez, J. Slater et al., “MED12 mutations in leiomyosarcoma and extrauterine leiomyoma,” Modern Pathology, vol. 26, no. 5, pp. 743–749, 2013.
- I. Panagopoulos, L. Gorunova, M. Brunetti et al., “Genetic heterogeneity in leiomyomas of deep soft tissue,” Oncotarget, vol. 8, no. 30, pp. 48769–48781, 2017.
Copyright © 2018 Aoife J. McCarthy and Runjan Chetty. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.